# Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub

> **NIH NIH U01** · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · 2024 · $995,246

## Abstract

In recent years, the NIH has awarded over $850M annually to the numerous research institutions and hospitals
within the Texas Medical Center (TMC; Houston, TX), producing ever-increasing numbers of biomedical discov-
eries. Despite this massive investment, only some of these discoveries advance to the clinic, and even fewer
are successfully commercialized to improve patient health and well-being. Texas academic entrepreneurs face
significant challenges as they seek to commercialize their discoveries, including a lack of training and resources
to support early-stage business and technology development. To address these deficiencies, we will establish
the Gulf Coast Consortium Research Evaluation and Commercialization Hub (GCC-REACH) as an inte-
grated multi-institutional resource wherein nascent academic entrepreneurs work closely with successful life
science experts and experienced biotech executives to develop strategic milestone-driven timelines to rapidly
validate the commercial value of their discoveries. GCC-REACH will expand the GCC and TMC infrastructure
and resources we have designed to support emerging biomedical companies. Academic entrepreneurs will hail
from all GCC-affiliated institutions (Baylor College of Medicine, Texas A&M Health Science Center, Houston
Methodist Research Institute, MD Anderson Cancer Center, Rice University, Texas Southern University, Univer-
sity of Houston, the University of Texas Health Science Center, University of Texas Medical Branch), Houston-
area colleges and universities with large historically-underrepresented groups, and other Texas research insti-
tutions. The GCC-REACH program will provide managerial oversight, access to vetted resources, and seed
funds to assist each entrepreneur in progressing to a clear value-added commercialization inflection point.
Significance. Discussions with numerous Texas-based researchers, all GCC-affiliated technology transfer of-
fices, successful life science companies, and healthcare investors have indicated widespread support for this
initiative, noting that it would help launch new companies and advance biomedical discoveries. Importantly,
GCC-REACH will pair entrepreneurs who balance full-time clinical, teaching, and laboratory duties with EIRs
and expert teams who will provide mentorship and assistance in completing the market analysis, business plans,
and technology development strategies.
Value proposition. In combination with substantial multi-institutional support, NIH's $4M investment will enable
GCC-REACH to train academic entrepreneurs to successfully commercialize novel discoveries. We expect these
entrepreneurs will launch approximately 60 highly-competitive early-stage biomedical companies that will be
highly competitive for non-dilutive NIH SBIR/STTR funding and venture investment.

## Key facts

- **NIH application ID:** 10932911
- **Project number:** 5U01GM152516-02
- **Recipient organization:** TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
- **Principal Investigator:** PETER J DAVIES
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $995,246
- **Award type:** 5
- **Project period:** 2023-09-25 → 2027-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10932911

## Citation

> US National Institutes of Health, RePORTER application 10932911, Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub (5U01GM152516-02). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10932911. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*